NCT00038428已完成2 期
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
Telik5 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2001年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 5
研究概览
简要总结
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologic diagnosis of ovarian cancer
- •Recurrent or persistent disease following primary therapy
- •Measurable disease
- •Prior treatment with at least one but no more than three prior chemotherapy regimens
- •Resistant or refractory to platinum-based chemotherapy
- •At least 18 years of age
- •Good performance status (ECOG 0 to 1)
- •Adequate liver, renal and bone marrow function
排除标准
- •Pregnant or currently breast feeding
- •Treatment with chemotherapy or immunotherapy within four weeks
- •Prior radiation to the whole pelvis
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung CancerCarcinoma, Non-small-cell LungNCT00047801Telik28
已完成
2 期
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung CancerCarcinoma, Non-small-cell LungNCT00040638Telik40
已完成
1 期
TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian CancerOvarian NeoplasmsNCT00051948Telik28
已完成
1 期
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT00077883Telik50
已完成
3 期
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian CancerOvarian NeoplasmsNCT00102973Telik244